Inhibition of human immunodeficiency virus-1 proliferation by liposome-encapsulated sense DNA to the 5' tat splice acceptor site. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Inhibition of human immunodeficiency virus-1 proliferation by liposome-encapsulated sense DNA to the 5' tat splice acceptor site.

Antisense Res Dev. 1992 Fall;2(3):187-97. Unique Identifier : AIDSLINE MED/93144890
Sullivan SM; Gieseler RK; Lenzner S; Ruppert J; Gabrysiak TG; Peters JH; Cox G; Richer L; Martin WJ; Scolaro MJ; Vestar, Inc., San Dimas, California.

Abstract: A liposome formulation containing a distearoylphosphatidylethanolamine analog was developed that was endocytosed by both lymphocytes and monocytes. This formulation was used to encapsulate sense and antisense 20-mer oligodeoxynucleotides to the 5' tat splice acceptor site of human immunodeficiency virus type 1. At a DNA concentration of 140 nM, the liposome-encapsulated sense DNA inhibited p24 production by as much as 84% in human peripheral blood leukocytes infected with wild-type virus. This treatment also reduced the number of peripheral blood leukocytes producing intracellular viral antigen by 71%. Of interest, no reduction in either parameter was observed for the antisense-containing liposomes. The results demonstrate the promise of a new liposomal delivery vehicle to inhibit human immunodeficiency virus replication by an entrapped oligodeoxynucleotide.
Keywords: Antiviral Agents/*PHARMACOLOGY Base Sequence Drug Carriers DNA, Antisense/*PHARMACOLOGY *DNA, Recombinant/*PHARMACOLOGY Endocytosis/DRUG EFFECTS Genes, tat/*DRUG EFFECTS Human HIV-1/*DRUG EFFECTS/GENETICS/PHYSIOLOGY Leukocytes/METABOLISM/MICROBIOLOGY Liposomes/PHARMACOKINETICS Molecular Sequence Data Oligonucleotides, Antisense/PHARMACOLOGY RNA Splicing Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Virus Replication/*DRUG EFFECTS/GENETICS JOURNAL ARTICLEKWDantiviralagents/KWDpharmacologybasesequencedrugcarriersdna,antisense/KWDpharmacologyKWDdna,recombinant/KWDpharmacologyendocytosis/drugeffectsgenes,tat/KWDdrugeffectshumanhiv-1/KWDdrugeffects/genetics/physiologyleukocytes/metabolism/microbiologyliposomes/pharmacokineticsmolecularsequencedataoligonucleotides,antisense/pharmacologyrnasplicingsupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDvirusreplication/KWDdrugeffects/geneticsjournalarticle
930530
M9350950

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .